These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23685539)

  • 1. Dynamic analysis of cardiac rhythms for discriminating atrial fibrillation from lethal ventricular arrhythmias.
    DeMazumder D; Lake DE; Cheng A; Moss TJ; Guallar E; Weiss RG; Jones SR; Tomaselli GF; Moorman JR
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):555-61. PubMed ID: 23685539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT.
    Tompkins CM; McNitt S; Polonsky B; Daubert JP; Wang PJ; Moss AJ; Zareba W; Kutyifa V
    J Cardiovasc Electrophysiol; 2017 Jan; 28(1):94-102. PubMed ID: 27696593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age.
    Chang PM; Powell BD; Jones PW; Carter N; Hayes DL; Saxon LA
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1183-1190. PubMed ID: 27334356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.
    Fischer A; Ousdigian KT; Johnson JW; Gillberg JM; Wilkoff BL
    Heart Rhythm; 2012 Jan; 9(1):24-31. PubMed ID: 21835150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.
    Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS; Bockstall K; Weinstock J; Alsheikh-Ali AA; Semsarian C; Estes NAM; Spirito P; Haas TS; Rowin EJ; Maron MS; Maron BJ
    J Cardiovasc Electrophysiol; 2017 May; 28(5):531-537. PubMed ID: 28240435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.
    Tsai VW; Cooper J; Garan H; Natale A; Ptaszek LM; Ellinor PT; Hickey K; Downey R; Zei P; Hsia H; Wang P; Hunt S; Haddad F; Al-Ahmad A
    Circ Heart Fail; 2009 May; 2(3):197-201. PubMed ID: 19808340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
    Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
    J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation of atrial fibrillation in Brugada syndrome patients with an implantable cardioverter defibrillator to prevent inappropriate shocks resulting from rapid atrial fibrillation.
    Sairaku A; Yoshida Y; Nakano Y; Kihara Y
    Int J Cardiol; 2013 Oct; 168(6):5273-6. PubMed ID: 23988302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failed anti-tachycardia pacing can be used to differentiate atrial arrhythmias from ventricular tachycardia in implantable cardioverter-defibrillators.
    Michael KA; Enriquez A; Baranchuk A; Haley C; Caldwell J; Simpson CS; Abdollah H; Redfearn DP
    Europace; 2015 Jan; 17(1):78-83. PubMed ID: 25031236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.
    Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 20. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.